Dr. Andrea Doni is the Head of the Imaging Unit at IRCCS Humanitas Research Hospital. Doni obtained a PhD in Immunology and Immunopathology from the Open University of London. From 1995 to 2005, he worked in the Department of Immunology directed by Professor Alberto Mantovani at the Pharmacological Institute Mario Negri of Milan, before moving in 2005 to IRCCS Humanitas Research Hospital. He specializes in studies of preclinical research with specific expertise in experimental in vivo models of humoral resistance against pathogens, in prognostic and predictive biomarker discovery of inflammatory diseases, and involvement of components of the innate immune system in tissue repair. Since 2002, he has dealt with advanced optical microscopy. He maintains and develops optical technologies for basic and advanced research, in linear (wide field fluorescence; Live Cell Imaging; confocal microscopy; FRAP, FLIP, TIRF, Photoactivation; Photoconversion; Uncaging) and non-linear (super-resolution STED; FLIM-based FRET; 2P excitation) microscopy. He developed different protocols and in vitro and in vivo experimental models for confocal and intravital optical microscopy analysis. His further current interest is in multiparametric spatial analysis of tissue using Imaging Mass Cytometry systems.
Prof. Alessandro Rambaldi is a Full Professor of Hematology at the Department of Oncology and Hematology at the University of Milan, Italy. Following his medical degree, he was an Associate in Pathology at the Dana Farber Cancer Institute, Boston, MA, USA. Since 2006, he has been the Director of the Hematology and Bone Marrow Transplant Unit at the Ospedale Papa Giovanni XXIII, Bergamo, Italy. He is a member of the American Society of Hematology (ASH), the European Hematology Association (EHA), and the European Blood and Marrow Transplant Group (BMT). From 2010 to 2015, he served JACIE as Vice Chair and Chair. From 2011 to 2014, he was President of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). His scientific interests range from translational research to academic clinical trials in which he pioneered the integration of molecular evaluation of minimal residual disease in the treatment strategy of adult patients with acute lymphoblastic leukemia and non-Hodgkin lymphomas. He also led several trials in the field of acute leukemia, lymphomas chronic myeloproliferative neoplasms, and allogeneic stem cell transplantation. His current special research interest is in the development
of innovative cellular therapies for the treatment of leukemia relapse after allogeneic stem cell transplantation.
